86798-59-6
86798-59-6
Chemical Structure
CI-930
- CAS No.: 86798-59-6
- Formula:C14H14N4O
- Molecular Weight:254.29
InChIKey: AEZZPAQOEUQNBB-UHFFFAOYSA-N
SMILES: O=C1NN=C(C(C1)C)C2=CC=C(N3C=NC=C3)C=C2
Biological Activity: CI-930 is a selective, orally active phosphodiesterase 3 (PDE3) inhibitor with an IC50 value of 0.0.84 μM. CI-930 exerts positive inotropic and vasodilatory effects by inhibiting cAMP hydrolysis. CI-930 also regulates hemodynamics, inhibits the proliferation of coronary artery smooth muscle cells, and suppresses the proliferation of mouse splenocytes. CI-930 can be used in research related to heart failure, atherosclerosis, and asthma[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CI-930 | CI-930 is a selective, orally active phosphodiesterase 3 (PDE3) inhibitor with an IC50 value of 0.0.84 μM. CI-930 exerts positive inotropic and vasodilatory effects by inhibiting cAMP hydrolysis. CI-930 also regulates hemodynamics, inhibits the proliferation of coronary artery smooth muscle cells, and suppresses the proliferation of mouse splenocytes. CI-930 can be used in research related to heart failure, atherosclerosis, and asthma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Murali S, et al. Acute Hemodynamic and Hormonal Effects of CI-930, a New Phosphodiesterase Inhibitor, in Severe Congestive Heart Failure. The American Journal of Cardiology. 1987;59(15):1356-1360.
- [2]. Jafri SM, et al. Hemodynamic, Pharmacokinetic and Clinical Response to CI-930 in Congestive Heart Failure Due to Ischemic or Dilated Cardiomyopathy. The American Journal of Cardiology. 1987;59(11):1126-1130. [Content Brief]
- [3]. Johnson-Mills K, et al. Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl) phenyl]-5-methyl-monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. Biochemical pharmacology. 1998 Oct 15;56(8):1065-73. [Content Brief]
- [4]. Lewis GM, et al. Effects of rolipram and CI-930 on IL-2 mRNA transcription in human Jurkat cells. Agents and actions. 1993;39 Spec No:C89-92. [Content Brief]
- [5]. Howell RE, et al. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulmonary pharmacology. 1995;8(2-3):83-9. [Content Brief]
- [6]. Gouault N et al. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents. J Pharm Pharmacol. 2004 Aug;56(8):1029-37. [Content Brief]
